# Igor Tsaur

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 130 papers | 2,528 citations | 201385 27 h-index | 276539 41 g-index |
| 135 all docs | 135 docs citations | 135 times ranked | 3809 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Telemedicine Online Visits in Urology During the COVID-19 Pandemicâ€"Potential, Risk Factors, and Patientsâ€™ Perspective. European Urology, 2020, 78, 16-20. | 0.9 | 168 |
| 2 | Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. European Urology, 2019, 76, 493-504. | 0.9 | 111 |
| 3 | Expression of Foxp3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer. PLoS ONE, 2013, 8, e53630. | 1.1 | 74 |
| 4 | TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. International Journal of Oncology, 2015, 47, 857-866. | 1.4 | 69 |
| 5 | Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2. PLoS ONE, 2014, 9, e105590. | 1.1 | 64 |
| 6 | Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. Cells, 2020, 9, 2643. | 1.8 | 63 |
| 7 | External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142. | 0.9 | 55 |
| 8 | Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals. Canadian Urological Association Journal, 2015, 9, 713. | 0.3 | 55 |
| 9 | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. Cancer Research and Treatment, 2015, 47, 306-312. | 1.3 | 52 |
| 10 | Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clinical and Experimental Metastasis, 2011, 28, 479-491. | 1.7 | 47 |
| 11 | Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581. | 2.6 | 46 |
| 12 | Direct lymphangiography as treatment option of lymphatic leakage: Indications, outcomes and role in patient's management. European Journal of Radiology, 2014, 83, 2167-2171. | 1.2 | 45 |
| 13 | Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sciences, 2016, 147, 137-142. | 2.0 | 45 |
| 14 | De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. BJU International, 2011, 108, 229-234. | 1.3 | 44 |
| 15 | Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 377-383. | 0.8 | 44 |
| 16 | R.E.N.A.L. Score Outperforms PADUA Score, C-Index and DAP Score for Outcome Prediction of Nephron Sparing Surgery in a Selected Cohort. Journal of Urology, 2016, 196, 664-671. | 0.2 | 44 |
| 17 | Prostate Cancer on the Webâ€"Expedient Tool for Patientsâ€™ Decision-Making?. Journal of Cancer Education, 2017, 32, 135-140. | 0.6 | 44 |
| 18 | HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Molecular Cancer, 2014, 13, 152. | 7.9 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Letters, 2011, 313, 84-90. | 3.2 | 41 |
| 20 | Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Letters, 2012, 324, 83-90. | 3.2 | 40 |
| 21 | Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. World Journal of Urology, 2019, 37, 243-251. | 1.2 | 37 |
| 22 | Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo. PLoS ONE, 2013, 8, e53100. | 1.1 | 35 |
| 23 | Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis. Cancers, 2021, 13, 882. | 1.7 | 35 |
| 24 | Development of urological cancers in renal transplant recipients: 30â€year experience at the Frankfurt Transplant Center. Cancer Science, 2010, 101, 2430-2435. | 1.7 | 34 |
| 25 | Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro. PLoS ONE, 2014, 9, e110244. | 1.1 | 34 |
| 26 | Amygdalin inhibits the growth of renal cell carcinoma cells in vitro. International Journal of Molecular Medicine, 2016, 37, 526-532. | 1.8 | 32 |
| 27 | Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 529.e11-529.e22. | 0.8 | 31 |
| 28 | Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sciences, 2011, 88, 418-424. | 2.0 | 29 |
| 29 | Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. European Journal of Cancer, 2010, 46, 2314-2323. | 1.3 | 27 |
| 30 | Crossâ€communication between histone H3 and H4 acetylation and Aktâ€m<scp>TOR</scp> signalling in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1460-1466. | 1.6 | 27 |
| 31 | sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. Journal of Experimental and Clinical Cancer Research, 2015, 34, 43. | 3.5 | 27 |
| 32 | How can we expand active surveillance criteria in patients with lowâ€and intermediateâ€risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830. | 1.3 | 27 |
| 33 | Robot-assisted simple prostatectomy versus open simple prostatectomy: a single-center comparison. World Journal of Urology, 2021, 39, 149-156. | 1.2 | 26 |
| 34 | Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer, 2011, 11, 375. | 1.1 | 25 |
| 35 | Molecular analysis of sunitinib resistant renal cell carcinomaÂcells after sequential treatment with <scp>RAD</scp>001Â(everolimus) or sorafenib. Journal of Cellular and Molecular Medicine, 2015, 19, 430-441. | 1.6 | 24 |
| 36 | HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anti-Cancer Drugs, 2011, 22, 1002-1009. | 0.7 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Aggressive variants of prostate cancer â€“ Are we ready to apply specific treatment right now?. Cancer Treatment Reviews, 2019, 75, 20-26. | 3.4 | 23 |
| 38 | Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro. Oncotarget, 2016, 7, 85208-85219. | 0.8 | 23 |
| 39 | Low dosed interferon alpha augments the antiâ€tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate, 2012, 72, 1719-1735. | 1.2 | 22 |
| 40 | Risk factors, complications and management of lymphocele formation after radical prostatectomy: A miniâ€review. International Journal of Urology, 2019, 26, 711-716. | 0.5 | 22 |
| 41 | Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney International, 2011, 79, 1005-1012. | 2.6 | 21 |
| 42 | Making surgery safer by centralization of care: impact of case load in penile cancer. World Journal of Urology, 2020, 38, 1385-1390. | 1.2 | 21 |
| 43 | Online Discussion on #KidneyStones: A Longitudinal Assessment of Activity, Users and Content. PLoS ONE, 2016, 11, e0160863. | 1.1 | 20 |
| 44 | Hereditary prostate cancer â€“ Primetime for genetic testing?. Cancer Treatment Reviews, 2019, 81, 101927. | 3.4 | 20 |
| 45 | Development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection is independent of surgical approach: a single-center analysis. International Urology and Nephrology, 2019, 51, 633-640. | 0.6 | 20 |
| 46 | Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic. World Journal of Urology, 2021, 39, 3139-3145. | 1.2 | 20 |
| 47 | HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression. Cells, 2018, 7, 129. | 1.8 | 19 |
| 48 | Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. European Urology Focus, 2021, 7, 742-751. | 1.6 | 19 |
| 49 | Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin Î±5â€“ and Integrin Î²3â€“Dependent Mechanism. Neoplasia, 2014, 16, 291-300. | 2.3 | 18 |
| 50 | Hidradenitis suppurativa gains increasing interest on World Wide Web: a source for patient information?. International Journal of Dermatology, 2017, 56, 726-732. | 0.5 | 18 |
| 51 | Transitional Cell Carcinoma of the Native Urinary Tract After Kidney Transplantation: Recommendations Following a Long-Term Retrospective Analysis. American Journal of the Medical Sciences, 2011, 341, 478-483. | 0.4 | 17 |
| 52 | Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism. International Journal of Molecular Medicine, 2016, 37, 843-850. | 1.8 | 17 |
| 53 | A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754. | 2.6 | 17 |
| 54 | Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World Journal of Urology, 2021, 39, 1387-1403. | 1.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget, 2017, 8, 110016-110028. | 0.8 | 17 |
| 56 | Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Letters, 2011, 301, 17-28. | 3.2 | 16 |
| 57 | Imaging modalities in synchronous oligometastatic prostate cancer. World Journal of Urology, 2019, 37, 2573-2583. | 1.2 | 16 |
| 58 | Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 486-495. | 0.7 | 15 |
| 59 | Towards data-driven medical imaging using natural language processing in patients with suspected urolithiasis. International Journal of Medical Informatics, 2020, 137, 104106. | 1.6 | 15 |
| 60 | Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96. | 0.9 | 15 |
| 61 | Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. Cancers, 2019, 11, 566. | 1.7 | 14 |
| 62 | Insulin-like Growth Factor-1 Influences Prostate Cancer Cell Growth and Invasion through an Integrin Î±3, Î±5, Î±V, and Î²1 Dependent Mechanism. Cancers, 2022, 14, 363. | 1.7 | 14 |
| 63 | Robotic Prostatectomy on the Web: A Cross-Sectional Qualitative Assessment. Clinical Genitourinary Cancer, 2016, 14, e355-e362. | 0.9 | 13 |
| 64 | Websites on Bladder Cancer: an Appropriate Source of Patient Information?. Journal of Cancer Education, 2019, 34, 381-387. | 0.6 | 13 |
| 65 | Focal Therapy for Prostate Cancer: Complications and Their Treatment. Frontiers in Surgery, 2021, 8, 696242. | 0.6 | 13 |
| 66 | Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells. Frontiers in Oncology, 2022, 12, 789284. | 1.3 | 13 |
| 67 | Association of Intravesical Tumor Location With Metastases to the Pelvic Lymph Nodes in Transitional Cell Cancer of the Bladder. American Journal of the Medical Sciences, 2010, 339, 341-344. | 0.4 | 12 |
| 68 | Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. International Urology and Nephrology, 2018, 50, 1821-1827. | 0.6 | 12 |
| 69 | Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment. World Journal of Urology, 2021, 39, 27-36. | 1.2 | 12 |
| 70 | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210819. | 1.4 | 12 |
| 71 | Intensified antineoplastic effect by combining an <scp>HDAC</scp>â€inhibitor, an <scp>mTOR</scp>â€inhibitor and low dosed interferon alpha in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 1795-1804. | 1.6 | 11 |
| 72 | mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro. Molecular Medicine Reports, 2017, 16, 7064-7071. | 1.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Risk factors and molecular characterization of penile cancer. Current Opinion in Urology, 2020, 30, 202-207. | 0.9 | 11 |
| 74 | Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE, 2020, 15, e0237248. | 1.1 | 11 |
| 75 | Use of psychoâ€oncological services by prostate cancer patients: A multilevel analysis. Cancer Medicine, 2020, 9, 3680-3690. | 1.3 | 11 |
| 76 | The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Investigational New Drugs, 2013, 31, 265-272. | 1.2 | 10 |
| 77 | Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. Advances in Therapy, 2020, 37, 592-602. | 1.3 | 10 |
| 78 | Testicular Cancer on the Webâ€"an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?. Journal of Cancer Education, 2018, 33, 1314-1322. | 0.6 | 9 |
| 79 | Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway. Cancers, 2022, 14, 1114. | 1.7 | 9 |
| 80 | Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomarkers, 2012, 10, 195-204. | 0.8 | 8 |
| 81 | Smartglass augmented realityâ€assisted targeted prostate biopsy using cognitive pointâ€ofâ€care fusion technology. International Journal of Medical Robotics and Computer Assisted Surgery, 2022, 18, e2366. | 1.2 | 8 |
| 82 | Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells. Cancers, 2022, 14, 3111. | 1.7 | 8 |
| 83 | Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 999-1005. | 0.8 | 7 |
| 84 | Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. Cancers, 2019, 11, 777. | 1.7 | 7 |
| 85 | Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e1-929.e10. | 0.8 | 7 |
| 86 | Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253. | 1.6 | 7 |
| 87 | Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer. Journal of Clinical Medicine, 2020, 9, 2501. | 1.0 | 7 |
| 88 | A realâ€world comparison of docetaxel versus abiraterone acetate for metastatic hormoneâ€sensitive prostate cancer. Cancer Medicine, 2021, 10, 6354-6364. | 1.3 | 7 |
| 89 | Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget, 2016, 7, 20410-20424. | 0.8 | 7 |
| 90 | Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Central European Journal of Urology, 2016, 69, 247-251. | 0.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World Journal of Urology, 2015, 33, 1051-1056. | 1.2 | 6 |
| 92 | Nationwide analysis on the impact of socioeconomic land use factors and incidence of urothelial carcinoma. Cancer Epidemiology, 2018, 52, 63-69. | 0.8 | 6 |
| 93 | Systemic treatment of penile squamous cell carcinomaâ€"hurdles and hopes of preclinical models and clinical regimens: a narrative review. Translational Andrology and Urology, 2021, 10, 4085-4098. | 0.6 | 6 |
| 94 | Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer. Cancers, 2021, 13, 2323. | 1.7 | 6 |
| 95 | Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84. | 0.9 | 6 |
| 96 | Utilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey. Patient Safety in Surgery, 2015, 9, 37. | 1.1 | 5 |
| 97 | PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases. Cancer Biomarkers, 2015, 15, 311-316. | 0.8 | 5 |
| 98 | What should be the patient's preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital. Patient Preference and Adherence, 2016, Volume 10, 2181-2187. | 0.8 | 5 |
| 99 | Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. Frontiers in Surgery, 2021, 8, 691473. | 0.6 | 5 |
| 100 | Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. Cancers, 2021, 13, 4511. | 1.7 | 5 |
| 101 | Incidence, Risk Factors and Management of Symptomatic Lymphoceles after Radical Retropubic Prostatectomy. Urology Practice, 2017, 4, 493-498. | 0.2 | 4 |
| 102 | CT-guided nephrostomyâ€"An expedient tool for complex clinical scenarios. European Journal of Radiology, 2019, 110, 142-147. | 1.2 | 4 |
| 103 | AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. Urologia Internationalis, 2020, 104, 253-262. | 0.6 | 4 |
| 104 | Radical Prostatectomy: Sequelae in the Course of Time. Frontiers in Surgery, 2021, 8, 684088. | 0.6 | 4 |
| 105 | Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. Nutrients, 2022, 14, 369. | 1.7 | 4 |
| 106 | Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. Dentistry Journal, 2016, 4, 28. | 0.9 | 3 |
| 107 | Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxelâ€"A Real-world Data Assessment. European Urology Focus, 2021, 7, 1308-1315. | 1.6 | 3 |
| 108 | Robotic surgery can be safely performed for patients and healthcare workers during COVIDâ€19 pandemic. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2291. | 1.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Acquired resistance to temsirolimus is associated with integrin Î±7 driven chemotactic activity of renal cell carcinoma in vitro. Oncotarget, 2018, 9, 18747-18759. | 0.8 | 3 |
| 110 | Predictors of Unfavorable Pathology in Patients with Incidental (pT1aâ€“T1b) Prostate Cancer. European Urology Focus, 2022, , . | 1.6 | 3 |
| 111 | Strategy of robotic surgeons to exert public influence through Twitter. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1739. | 1.2 | 2 |
| 112 | Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. Scandinavian Journal of Urology, 2017, 51, 342-344. | 0.6 | 2 |
| 113 | Outreach and Influence of Surgical Societiesâ€™ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemicâ€”An Anonymized International Urologic Expert Inquiry. Urology, 2020, 145, 73-78. | 0.5 | 2 |
| 114 | Phase 2 of the Coronavirus Pandemic in Urology: Ramping Up Surgical Caseload and Resident Training while COVID-19 Infections Decrease. Urologia Internationalis, 2021, 105, 1-2. | 0.6 | 2 |
| 115 | Molecular Mechanisms Related with Oligometastatic Prostate Cancerâ€”Is It Just a Matter of Numbers?. Cancers, 2022, 14, 766. | 1.7 | 2 |
| 116 | Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancerâ€”Current State and Future Perspectives. Cancers, 2022, 14, 147. | 1.7 | 2 |
| 117 | Rare Case of Excessive Beta-Human Chorionic Gonadotropin Producing Intrascrotal Leiomyosarcoma: Diagnostic Pitfalls and Therapeutic Implications. Clinical Genitourinary Cancer, 2016, 14, e409-e412. | 0.9 | 1 |
| 118 | Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. World Journal of Urology, 2018, 36, 1489-1494. | 1.2 | 1 |
| 119 | AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?. World Journal of Urology, 2018, 36, 149-151. | 1.2 | 1 |
| 120 | sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 355.e1-355.e9. | 0.8 | 1 |
| 121 | Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 205-216. | 3.9 | 1 |
| 122 | The timing of initial imaging in testicular cancer: impact on radiological findings and clinical decision making. Minerva Urology and Nephrology, 2022, 74, . | 1.3 | 1 |
| 123 | Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer. Cancers, 2022, 14, 1683. | 1.7 | 1 |
| 124 | Corrigendum to â€œTumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancerâ€•[European Journal of Cancer 46 (12) (2010) 2314â€“2323]. European Journal of Cancer, 2011, 47, 2373. | 1.3 | 0 |
| 125 | Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?. Memo - Magazine of European Medical Oncology, 2018, 11, 297-300. | 0.3 | 0 |
| 126 | Combining anticancer drugs with osteoprotective agents in prostate cancerâ€”A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology. European Urology, 2021, 79, 895-896. | 0.9 | 0 |
| 128 | Deciphering the Molecular Machineryâ€"Influence of sE-Cadherin on Tumorigenic Traits of Prostate Cancer Cells. Biology, 2021, 10, 1007. | 1.3 | 0 |
| 129 | The timing of initial imaging in testicular cancer: impact on radiological findings and clinical decision making. Minerva Urology and Nephrology, 2021, , . | 1.3 | 0 |
| 130 | Highâ€"Normal Preoperative Potassium Level Is Associated with Reduced 30â€"Day Morbidity and Shorter Hospital Stay after Radical Cystectomy. Journal of Clinical Medicine, 2022, 11, 1174. | 1.0 | 0 |